Amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane salts and methods for making them
The synthesis of amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salts addresses purity and stability issues in Imetelstat synthesis, enhancing its efficacy as a telomerase inhibitor for cancer treatment.
Patent Information
- Application Number
- JP2022524998
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-28
- Filing Date
- 2020-10-23
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-10-23
AI Technical Summary
Existing methods for synthesizing Imetelstat, a telomerase inhibitor, face challenges in achieving high purity and stability of the N3'→P5' thiophosphoramidate oligonucleotide component, which is crucial for its efficacy in inhibiting telomerase activity and treating cancer.
The synthesis of amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salts is developed, involving the preparation of fatty acid metal salts through precipitation from solvents, ensuring high purity and stability of the oligonucleotide component.
The amorphous solid compositions enhance the stability and purity of Imetelstat, improving its effectiveness as a telomerase inhibitor for treating hematological malignancies and achieving complete clinical remission in myelofibrosis patients.
Smart Images

Figure 0007577742000016 
Figure 0007577742000017 
Figure 0007577742000018
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 926,778, filed October 28, 2019, the disclosure of which is incorporated herein by reference.
[0002] Introduction Imetelstat is a telomerase inhibitor that binds with high affinity to the template region of the RNA component of telomerase. Studies have shown that imetelstat inhibits telomerase activity and is effective against cell proliferation in many different cancer cell lines and human tumors. Imetelstat has been used in clinical trials in patients with hematological malignancies. Clinical trials in patients with myelofibrosis have shown that imetelstat can achieve complete clinical remission in certain patients.
[0003] The structure of Imetelstat comprises an N3'→P5' thiophosphoramidate oligonucleotide. Imetelstat has been synthesized by solid-phase oligonucleotide synthesis, where the first phosphoramidite nucleotide is attached to the support and subsequently sulfurized. Chain extension of the oligonucleotide building blocks is achieved by repeated reaction of the 3'-amino group of the solid-support-bound oligonucleotide with additional nucleotide phosphoramidite monomers. Imetelstat oligonucleotides are attached to the solid support through a palmitoyl-amide linker. This fatty acid-amide linker is therefore a building block in the synthesis of Imetelstat. Summary of the Invention [Means for solving the problem]
[0004] Aspects of the disclosure include methods for preparing an amorphous solid composition of fatty acid metal salt. In embodiments, the subject method includes preparing a fatty acid metal salt from a fatty acid organic salt and precipitating the fatty acid metal salt from a solvent to produce an amorphous solid composition of fatty acid metal salt. In carrying out the subject method according to certain embodiments, a succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base to produce a succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt, and the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is precipitated in a solvent to produce an amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition. (Scheme I) [ka] In the formula, R is C 10 -C 20 Fatty acids (e.g. C 16 fatty acid), and PG is a protecting group.
[0005] In some embodiments, the metal is lithium. In some embodiments, the fatty acid is selected from palmitic acid, stearic acid, oleic acid, linoleic acid, myristoleic acid, and batyl fatty acid. In some embodiments, the protected hydroxy group includes a dimethoxy-triphenylmethyl protecting group. In certain embodiments, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is a compound of formula I. [ka] The amorphous composition may be formed as a crude composition. In certain cases, the fatty acid metal salt may be characterized by the presence or absence of a crystalline structure, for example by high performance liquid chromatography (HPLC), proton nuclear magnetic resonance spectroscopy ( 1 1 H NMR), or a combination thereof) of 95% or greater by weight of the crude composition.
[0006] In some embodiments, precipitating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt to form an amorphous solid composition comprises: 1) heating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt in a non-polar solvent to form a heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition; and 2) cooling the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition to form an amorphous solid of the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt. In certain cases, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is heated in a non-polar solvent to a temperature of about 45° C. to about 55° C., such as about 50° C. To precipitate the amorphous solid composition, the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition may be cooled to a temperature of about -5°C to about 5°C, such as about 0°C, to produce an amorphous solid composition. In certain cases, cooling the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition comprises adding the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition back to a cold non-polar solvent. The precipitated amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition can be isolated by filtration.
[0007] In certain embodiments, the method further comprises contacting the 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane with succinic anhydride in the presence of an organic base to succinylate the 2-hydroxy group of the 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane to prepare a succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt. In some cases, the 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane is contacted with succinic anhydride in a polar solvent.
[0008] The disclosed aspects also include an amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane lithium salt. In some embodiments, the fatty acid is selected from palmitic acid, stearic acid, oleic acid, linoleic acid, myristoleic acid, and batyl fatty acid. In some embodiments, the protected hydroxy group includes a dimethoxy-triphenylmethyl protecting group. In certain embodiments, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is a compound of formula I. [ka]
[0009] In some embodiments, the present disclosure provides an amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane lithium salt of formula I having a peak at about 19.5° 2θ in an X-ray powder diffraction pattern (XRPD) using Cu Kα radiation. In other embodiments, the present disclosure provides an amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane lithium salt of formula I in which thermogravimetric analysis (TGA) exhibits a single weight loss step. In these embodiments, the single weight loss step may begin at about 225° C. The subject amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane lithium salt of formula I may also be characterized by a TGA thermogram that exhibits a mass loss of less than 1% of the total mass of the sample upon heating between 30° C. and 300° C. In another embodiment, the present disclosure provides an amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane lithium salt of formula I, wherein the differential scanning calorimetry (DSC) curve exhibits an absorption peak at about 44.9° C. [Brief description of the drawings]
[0010] [Figure 1] 1 shows an X-ray powder diffraction pattern of an amorphous solid succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt according to certain embodiments. [Diagram 2] 1 shows a polarized light microscopy image of an amorphous solid succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt according to certain embodiments. [Diagram 3] 1 shows a thermogram from a thermogravimetric analysis (TGA) of an amorphous solid succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt, according to certain embodiments. [Figure 4]1 shows a plot from differential scanning calorimetry of an amorphous solid succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt, according to certain embodiments. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] Select a definition for a chemical term The following terms have the following meanings unless otherwise indicated: Any term not defined has its art-recognized meaning.
[0012] As used herein, the terms "phosphate" and "phosphate group" are meant to include thiophosphate groups and oxophosphate groups.
[0013] As used herein, the term "phosphoramidite amino group" refers to an amino group, --NR, that is attached to the phosphorus atom of a phosphoramidite group. 4 R 5 and the term "phosphoramidite nitrogen" refers to the nitrogen atom of a phosphoramidite amino group.
[0014] "Alkyl" refers to monovalent saturated aliphatic hydrocarbyl groups having 1 to 10 carbon atoms, such as 1 to 6 carbon atoms (e.g., "alkyl of 1 to 6 carbon atoms"), or 1 to 5 carbon atoms (e.g., "alkyl of 1 to 5 carbon atoms"), or 1 to 4 (e.g., "alkyl of 1 to 4 carbon atoms"), or 1 to 3 carbon atoms (e.g., "alkyl of 1 to 3 carbon atoms"). This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH3-), ethyl (CH3CH2-), n-propyl (CH3CH2CH2-), isopropyl ((CH3)2CH-), n-butyl (CH3CH2CH2CH2-), isobutyl ((CH3)2CHCH2-), sec-butyl ((CH3)(CH3CH2)CH-), t-butyl ((CH3)3C-), n-pentyl (CH3CH2CH2CH2CH2-), and neopentyl ((CH3)3CCH2-).
[0015] The term "substituted alkyl" refers to an alkyl group in which one or more carbon atoms of the alkyl chain are optionally substituted with -O-, -N-, -S-, -S(O), n - (n is 0-2), -NR- (R is hydrogen or alkyl), and other heteroatoms, such as alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-aryl, -SO2-heteroaryl, and -NR a R b (R a and R bmay be the same or different and are selected from the group consisting of hydrogen, optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, and heterocyclic. In some cases, "substituted alkyl" refers to an alkyl group, as defined herein, having 1 to 5 substituents selected from the group consisting of alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, thiol, thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, sulfonamide, and -NR a R b (R a and R b refers to an alkyl group, as defined herein, having 1 to 5 substituents selected from the group consisting of: which may be the same or different and are selected from hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, and heterocyclic.
[0016] "Alkylene" refers to an alkylene group that is either linear or branched, preferably has 1 to 6, more preferably 1 to 3 carbon atoms, and is optionally substituted with -O-, -NR 10 -, -NR 10 C(O)-, -C(O)NR 10 -, etc. This term includes, by way of example, methylene (-CH-), ethylene (-CHCH-), n-propylene (-CHCHCH-), iso-propylene (-CHCH(CH)-), (-C(CH)CHCH-), (-C(CH)CHC(O)-), (-C(CH)CHC(O)NH-), (-CH(CH)CH-), and the like.
[0017] "Substituted alkylene" refers to an alkylene group having one to three hydrogens replaced with a substituent, as described for carbon in the definition of "substituted" below.
[0018] The term "alkane" refers to alkyl and alkylene groups as defined herein.
[0019] The terms “alkylaminoalkyl”, “alkylaminoalkenyl”, and “alkylaminoalkynyl” refer to R ’ is an alkyl group as defined herein; R ” is an alkylene, alkenylene, or alkynylene group as defined herein; R ’ NHR ” - refers to the group.
[0020] The terms "alkaryl" or "aralkyl" refer to the groups -alkylene-aryl and -substituted alkylene-aryl, where alkylene, substituted alkylene, and aryl are defined herein.
[0021] "Alkoxy" refers to an -O-alkyl group, where alkyl is as defined herein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, n-pentoxy, and the like. The term "alkoxy" also refers to the groups alkenyl-O-, cycloalkyl-O-, cycloalkenyl-O-, and alkynyl-O-, where alkenyl, cycloalkyl, cycloalkenyl, and alkynyl are as defined herein.
[0022] The term "substituted alkoxy" refers to the groups substituted alkyl-O-, substituted alkenyl-O-, substituted cycloalkyl-O-, substituted cycloalkenyl-O-, and substituted alkynyl-O-, where substituted alkyl, substituted alkenyl, substituted cycloalkyl, substituted cycloalkenyl, and substituted alkynyl are as defined herein.
[0023] The term "alkoxyamino" refers to the group -NH-alkoxy, where alkoxy is defined herein.
[0024] The term "haloalkoxy" refers to an alkyl-O- group in which one or more hydrogen atoms on the alkyl group has been replaced with a halo group and includes, by way of example, groups such as trifluoromethoxy.
[0025] The term "haloalkyl" refers to a substituted alkyl group as defined above, in which one or more hydrogen atoms on the alkyl group have been replaced with a halo group. Examples of such groups include, but are not limited to, fluoroalkyl groups such as trifluoromethyl, difluoromethyl, trifluoroethyl, etc.
[0026] The term "alkylalkoxy" refers to the groups -alkylene-O-alkyl, alkylene-O-substituted alkyl, substituted alkylene-O-alkyl, and substituted alkylene-O-substituted alkyl, where alkyl, substituted alkyl, alkylene, and substituted alkylene are as defined herein.
[0027] The term "alkylthioalkoxy" refers to the groups -alkylene-S-alkyl, alkylene-S-substituted alkyl, substituted alkylene-S-alkyl, and substituted alkylene-S-substituted alkyl, where alkyl, substituted alkyl, alkylene, and substituted alkylene are as defined herein.
[0028] "Alkenyl" refers to straight or branched chain hydrocarbyl groups having from 2 to 6 carbon atoms, preferably from 2 to 4 carbon atoms, and having at least one, and preferably one or two sites of double bond unsaturation. Examples of this term include but-yl, allyl, and but-3-en-1-yl. Included in this term are cis and trans isomers or mixtures of these isomers.
[0029] The term "substituted alkenyl" refers to an alkenyl group, as defined herein, having from one to five substituents, or from one to three substituents selected from alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, and -SO2-heteroaryl.
[0030] "Alkynyl" refers to a monovalent straight or branched chain hydrocarbyl group having from 2 to 6 carbon atoms, preferably from 2 to 3 carbon atoms, and having at least 1, and preferably 1 to 2 sites of triple bond unsaturation. Examples of such alkynyl groups include acetylenyl (-C≡CH) and propargyl (-CHC≡CH).
[0031] The term "substituted alkynyl" refers to an alkynyl group, as defined herein, having from one to five substituents, or from one to three substituents selected from alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, SO2-aryl, and -SO2-heteroaryl.
[0032] "Alkynyloxy" refers to an -O-alkynyl group, where alkynyl is as defined herein. Alkynyloxy includes, by way of example, ethynyloxy, propynyloxy, and the like.
[0033] "Acyl" refers to the groups alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein. For example, acyl includes the "acetyl" group CH3C(O)-.
[0034] "Acylamino" is R 20 is hydrogen or alkyl, where alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein; -NR 20 C(O)alkyl, -NR 20 C(O) substituted alkyl, NR 20 C(O)cycloalkyl, -NR 20 C(O)-substituted cycloalkyl, -NR 20 C(O)cycloalkenyl, -NR 20 C(O)-substituted cycloalkenyl, -NR 20 C(O)alkenyl, -NR 20 C(O) substituted alkenyl, -NR 20 C(O)alkynyl, -NR 20 C(O) substituted alkynyl, -NR 20 C(O)aryl, -NR 20 C(O) substituted aryl, -NR 20C(O)heteroaryl, -NR 20 C(O)-substituted heteroaryl, -NR 20 C(O) heterocyclic, and -NR 20 Refers to a C(O) substituted heterocyclic group.
[0035] The term "aminocarbonyl" or "aminoacyl" refers to R 21 and R 22 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; R 21 and R 22 optionally joined together with the nitrogen to which they are attached to form a heterocyclic or substituted heterocyclic group, where alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein; —C(O)NR 21 R 22 Refers to the base.
[0036] "Aminocarbonylamino" is R 21 , R 22 , and R 23 is independently selected from hydrogen, alkyl, aryl, or cycloalkyl, and two R groups are joined to form a heterocyclyl group; 21 C(O)NR 22 R 23 Refers to the base.
[0037] The term "alkoxycarbonylamino" refers to the group -NRC(O)OR, where each R is independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, or heterocyclyl, where alkyl, substituted alkyl, aryl, heteroaryl, and heterocyclyl are as defined herein.
[0038] The term "acyloxy" refers to the groups alkyl-C(O)O-, substituted alkyl-C(O)O-, cycloalkyl-C(O)O-, substituted cycloalkyl-C(O)O-, aryl-C(O)O-, heteroaryl-C(O)O-, and heterocyclyl-C(O)O-, where alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl, and heterocyclyl are as defined herein.
[0039] "Aminosulfonyl" is R 21 and R 22 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; R 21 and R 22 optionally, together with the nitrogen to which they are attached, form a heterocyclic or substituted heterocyclic group, where alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein; -SONR 21 R 22 Refers to the base.
[0040] "Sulfonylamino" is R 21 and R 22is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; R 21 and R 22 optionally joined together with the nitrogen to which they are attached to form a heterocyclic or substituted heterocyclic group, where alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein; -NR 21 SO2R 22 Refers to...
[0041] "Aryl" or "Ar" refers to a monovalent aromatic carbocyclic group of 6 to 18 carbon atoms having a single ring (such as is present in a phenyl group), or a ring system having multiple fused rings, which may or may not be aromatic, provided that the point of attachment is through an atom of an aromatic ring (examples of such aromatic ring systems include naphthyl, anthryl, and indanyl). Examples of this term include phenyl and naphthyl. Unless otherwise constrained by the definition of the aryl substituents, such aryl groups may be optionally substituted with one to five substituents, or one to three substituents selected from acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, -SO2-heteroaryl, and trihalomethyl. In such cases, the aryl group is substituted with one to five substituents (eg, as described herein) is referred to as a "substituted aryl."
[0042] "Aryloxy" refers to the group --O-aryl, where aryl is as defined herein, and includes optionally substituted aryl groups as defined herein, including, by way of example, phenoxy, naphthoxy, and the like.
[0043] "Amino" refers to the group -NH2.
[0044] The term "substituted amino" refers to the group -NRR where each R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl, and heterocyclyl, provided that at least one R is not hydrogen.
[0045] The term "azido" refers to the group --N3.
[0046] "Carboxyl", "carboxy", or "carboxylate" refers to -COH or a salt thereof.
[0047] The term "carboxyl ester" or "carboxy esters", or "carboxyalkyl" or "carboxylalkyl" refers to any of the following: alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein, -C(O)O-alkyl, -C(O) This refers to the groups O-substituted alkyl, -C(O)O-alkenyl, -C(O)O-substituted alkenyl, -C(O)O-alkynyl, -C(O)O-substituted alkynyl, -C(O)O-aryl, -C(O)O-substituted aryl, -C(O)O-cycloalkyl, -C(O)O-substituted cycloalkyl, -C(O)O-cycloalkenyl, -C(O)O-substituted cycloalkenyl, -C(O)O-heteroaryl, -C(O)O-substituted heteroaryl, -C(O)O-heterocyclic, and -C(O)O-substituted heterocyclic.
[0048] "(Carboxyl ester)oxy" or "carbonate" refers to -OC(O)O-alkyl, -OC(O)O-substituted alkyl, -OC(O)O-alkenyl, -OC(O)O-substituted alkyl, -OC(O)O-carbonyl, -OC(O)O-alkyl ... This refers to the groups -OC(O)O-substituted alkenyl, -OC(O)O-alkynyl, -OC(O)O-substituted alkynyl, -OC(O)O-aryl, -OC(O)O-substituted aryl, -OC(O)O-cycloalkyl, -OC(O)O-substituted cycloalkyl, -OC(O)O-cycloalkenyl, -OC(O)O-substituted cycloalkenyl, -OC(O)O-heteroaryl, -OC(O)O-substituted heteroaryl, -OC(O)O-heterocyclic, and -OC(O)O-substituted heterocyclic.
[0049] "Cyano" or "nitrile" refers to the group --CN.
[0050] "Cycloalkyl" refers to cyclic alkyl groups of 3 to 10 carbon atoms having a single ring or multiple rings, including fused, bridged, and spirocyclic systems. Examples of suitable cycloalkyl groups include, for example, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like. Such cycloalkyl groups include, for example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like, or multiple ring structures such as adamantanyl.
[0051] The term "substituted cycloalkyl" refers to a cycloalkyl group having from 1 to 5 substituents, or from 1 to 3 substituents selected from alkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl and -SO2-heteroaryl.
[0052] "Cycloalkenyl" refers to a non-aromatic cyclic alkyl group of 3 to 10 carbon atoms having a single ring or multiple rings and having at least one double bond, preferably 1 to 2 double bonds.
[0053] The term "substituted cycloalkenyl" refers to a cycloalkenyl group having from 1 to 5 substituents, or from 1 to 3 substituents selected from alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl and -SO2-heteroaryl.
[0054] "Cycloalkynyl" refers to a non-aromatic cycloalkyl group of from five to ten carbon atoms having a single ring or multiple rings and having at least one triple bond.
[0055] "Cycloalkoxy" refers to -O-cycloalkyl.
[0056] "Cycloalkenyloxy" refers to -O-cycloalkenyl.
[0057] "Halo" or "halogen" refers to fluoro, chloro, bromo, and iodo.
[0058] "Hydroxy" or "hydroxyl" refers to the group --OH.
[0059] "Heteroaryl" refers to an aromatic group of 1-15 carbon atoms, such as 1-10 carbon atoms in the ring, and 1-10 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur. Such heteroaryl groups can have a single ring (such as pyridinyl, imidazolyl, or furyl) or multiple fused rings in the ring system (e.g., in groups such as indolizinyl, quinolinyl, benzofuran, benzimidazolyl, or benzothienyl), provided that at least one ring in the ring system is aromatic, but the point of attachment is through an aromatic ring atom. In certain embodiments, the nitrogen and / or sulfur ring atoms of the heteroaryl group are optionally oxidized to provide an N-oxide (N→O), sulfinyl, or sulfonyl moiety. The term includes, by way of example, pyridinyl, pyrrolyl, indolyl, thiophenyl, and furanyl. Unless otherwise constrained by the definition of the heteroaryl substituents, such heteroaryl groups may be optionally substituted with one to five substituents, or one to three substituents selected from acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl and -SO2-heteroaryl, and trihalomethyl. In such cases, the heteroaryl group is substituted with one to five substituents (eg, as described herein) is referred to as a "substituted heteroaryl."
[0060] The term "heteroaralkyl" refers to the group -alkylene-heteroaryl, where alkylene and heteroaryl are defined herein. This term includes, by way of example, pyridylmethyl, pyridylethyl, indolylmethyl, and the like.
[0061] "Heteroaryloxy" refers to -O-heteroaryl.
[0062] "Heterocycle", "heterocyclic", "heterocycloalkyl", and "heterocyclyl" refer to saturated or unsaturated groups having a single ring or multiple fused rings, including fused bridged and spiro ring systems, and having 3-20 ring atoms, including 1-10 heteroatoms. These ring atoms are selected from the group consisting of nitrogen, sulfur, or oxygen, and in fused ring systems, one or more of the rings may be cycloalkyl, aryl, or heteroaryl, but the point of attachment is through a non-aromatic ring. In certain embodiments, the nitrogen and / or sulfur ring atoms of the heterocyclic group are optionally oxidized to provide N-oxide, -S(O)-, or -SO2- moieties.
[0063] Examples of heterocycles and heteroaryls include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, dihydroindole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine. , isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydroisoquinoline, 4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene, benzo[b]thiophenol, morpholinyl, thiomorpholinyl (also called thiamorpholinyl), 1,1-dioxothiomorpholinyl, piperidinyl, pyrrolidine, tetrahydrofuranyl, and the like.
[0064] Unless otherwise constrained by the definition of the heterocyclic substituent, such heterocyclic groups may be optionally substituted with from 1 to 5, or from 1 to 3, substituents selected from alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, -SO2-heteroaryl, and fused heterocycle.
[0065] "Heterocyclyloxy" refers to the group --O-heterocyclyl.
[0066] The term "heterocyclylthio" refers to a heterocyclic -S- group.
[0067] The term "heterocyclene" refers to a diradical group formed from a heterocycle, as defined herein.
[0068] The term "hydroxyamino" refers to the group -NHOH.
[0069] "Nitro" refers to the -NO2 group.
[0070] "Oxo" refers to the atom (=O).
[0071] "Sulfonyl" refers to the groups SO2-alkyl, SO2-substituted alkyl, SO2-alkenyl, SO2-substituted alkenyl, SO2-cycloalkyl, SO2-substituted cycloalkyl, SO2-cycloalkenyl, SO2-substituted cycloalkenyl, SO2-aryl, SO2-substituted aryl, SO2-heteroaryl, SO2-substituted heteroaryl, SO2-heterocyclic, and SO2-substituted heterocyclic, where alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein. Examples of sulfonyl include methyl-SO2-, phenyl-SO2-, and 4-methylphenyl-SO2-.
[0072] "Sulfonyloxy" refers to the groups -OSO2-alkyl, OSO2-substituted alkyl, OSO2-alkenyl, OSO2-substituted alkenyl, OSO2-cycloalkyl, OSO2-substituted cycloalkyl, OSO2-cycloalkenyl, OSO2-substituted cycloalkenyl, OSO2-aryl, OSO2-substituted aryl, OSO2-heteroaryl, OSO2-substituted heteroaryl, OSO2-heterocyclic, and OSO2-substituted heterocyclic, where alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, ...heteroaryl, OSO2-substituted heteroaryl, OSO2-heterocyclic, and OSO2-substituted heterocyclic.
[0073] The term "aminocarbonyloxy" refers to the group -OC(O)NRR, where each R is independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, or heterocyclic, where alkyl, substituted alkyl, aryl, heteroaryl, and heterocyclic are as defined herein.
[0074] "Thiol" refers to the group --SH.
[0075] The term "thioxo" or "thioketo" refers to the atom (=S).
[0076] The term "alkylthio" or "thioalkoxy" refers to an -S-alkyl group, where alkyl is as defined herein. In certain embodiments, the sulfur can be oxidized to -S(O)-. The sulfoxide can exist as one or more stereoisomers.
[0077] The term "substituted thioalkoxy" refers to the group --S-substituted alkyl.
[0078] The term "thioaryloxy" refers to an aryl-S- group, where the aryl group is as defined herein, including optionally substituted aryl groups, also as defined herein.
[0079] The term "thioheteroaryloxy" refers to the group heteroaryl-S-, where the heteroaryl group is as defined herein, including optionally substituted heteroaryl groups, also as defined herein.
[0080] The term "thioheterocycloxy" refers to the group heterocyclyl-S-, where the heterocyclyl group is as defined herein, including optionally substituted heterocyclyl groups, which are also as defined herein.
[0081] Further to the disclosure herein, the term "substituted," when used to modify a specified group or radical, can also mean that one or more hydrogen atoms of the specified group or radical are replaced, each independently of one another, with the same or different substituents as defined below.
[0082] In addition to the groups disclosed for each individual term herein, one or more hydrogens on a saturated carbon atom of the specified group or radical (any two hydrogens on a single carbon may be substituted, such as ═O, ═NR 70 , =N-OR 70 , =N2 or =S), unless otherwise specified, are R 60 is selected from the group consisting of optionally substituted alkyl, cycloalkyl, heteroalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; each R 70 are independently hydrogen or R 60 And each R 80 But independently, R 70 or alternatively, two R 80’together with the nitrogen to which they are attached form a 5-, 6-, or 7-membered heterocycloalkyl which may optionally contain 1 to 4 additional heteroatoms, the same or different, selected from the group consisting of O, N, and S, the N's may have -H or C1-C3 alkyl substituents, and each M + is a counterion with a net single positive charge, -R 60 , halo, =O, -OR 70 , -SR 70 , -NR 80 R 80 , trihalomethyl, -CN, -OCN, -SCN, -NO, -NO2, =N2, -N3, -SO2R 70 , -SO2O - M + , -SO2OR 70 , -OSO2R 70 , -OSO2O - M + , -OSO2OR 70 , -P(O)(O - )2(M + )2, -P(O)(OR 70 )O - M + , -P(O)(OR 70 )2, -C(O)R 70 , -C(S)R 70 , -C(NR 70 )R 70 , -C(O)O - M + , -C(O)OR 70 , -C(S)OR 70 , -C(O)NR 80 R 80 , -C(NR 70 )NR 80 R 80 , -OC(O)R 70 , -OC(S)R 70 , -O-C(O)O - M + , -OC(O)OR 70 , -OC(S)OR 70 , -NR 70 C(O)R 70 , -NR 70 C(S)R 70 , -NR 70CO2 - M + , -NR 70 CO2R 70 , -NR 70 C(S)OR 70 , -NR 70 C(O)NR 80 R 80 , -NR 70 C(NR 70 )R 70 , and -NR 70 C(NR 70 )NR 80 R 80 Each M + are independently, e.g., K + , Na + , Li + Alkaline ions such as + N(R 60 )4, or [Ca 2+ ] 0.5 , [Mg 2+ ] 0.5 , or [Ba 2+ ] 0.5 (The subscript 0.5 means that one of the counterions of such divalent alkaline earth ion may be an ionized form of an inventive compound and the other counterion may be an ionized form such as chloride, or a two ionized compound disclosed herein may serve as a counterion of such divalent alkaline earth ion, or a doubly ionized compound of the inventive compound may serve as a counterion of such divalent alkaline earth ion. A specific example is -NR 80 R 80 is meant to include -NH2, -NH-alkyl, N-pyrrolidinyl, N-piperazinyl, 4N-methyl-piperazin-1-yl, and N-morpholinyl.
[0083] Further to the disclosure herein, the substitution of hydrogen on an unsaturated carbon atom of a “substituted” alkene, alkyne, aryl, and heteroaryl group is, unless otherwise specified, R 60 , R 70 , R 80 , and M. +is as previously defined, except that in the case of a substituted alkene or alkyne, the substituent is -O - M + , -OR 70 , -SR 70 , or -S - M + -R, provided that 60 , halo, -O - M + , -OR 70 , -SR 70 , -S - M + , -NR 80 R 80 , trihalomethyl, -CF3, -CN, -OCN, -SCN, -NO, -NO2, -N3, -SO2R 70 , -SO3 - M + , -SO3R 70 , -OSO2R 70 , -OSO3 - M + , -OSO3R 70 , -PO3 -2 (M + )2, -P(O)(OR 70 )O - M + , -P(O)(OR 70 )2, -C(O)R 70 , -C(S)R 70 , -C(NR 70 )R 70 , -CO2 - M + , -CO2R 70 , -C(S)OR 70 , -C(O)NR 80 R 80 , -C(NR 70 )NR 80 R 80 , -OC(O)R 70 , -OC(S)R 70 , -OCO2 - M + , -OCO2R 70 , -OC(S)OR 70 , -NR 70 C(O)R 70 , -NR 70 C(S)R 70, -NR 70 CO2 - M + , -NR 70 CO2R 70 , -NR 70 C(S)OR 70 , -NR 70 C(O)NR 80 R 80 , -NR 70 C(NR 70 )R 70 and -NR 70 C(NR 70 )NR 80 R 80 It is.
[0084] In addition to the groups disclosed for each individual term herein, the substituents of the hydrogen on the nitrogen atom of "substituted" heteroalkyl and cycloheteroalkyl groups are, unless otherwise specified, R 60 , R 70 , R 80 , and M. + is as previously defined, -R 60 , -O - M + , -OR 70 , -SR 70 , -S - M + , -NR 80 R 80 , trihalomethyl, -CF3, -CN, -NO, -NO2, -S(O)2R 70 , -S(O)O - M + , -S(O)2OR 70 , -OS(O)2R 70 , -OS(O)2O - M + , -OS(O)2OR 70 , -P(O)(O - )2(M + )2, -P(O)(OR 70 )O - M + , -P(O)(OR 70 )(OR 70 ), -C(O)R 70 , -C(S)R 70 , -C(NR 70 )R70 , -C(O)OR 70 , -C(S)OR 70 , -C(O)NR 80 R 80 , -C(NR 70 )NR 80 R 80 , -OC(O)R 70 , -OC(S)R 70 , -OC(O)OR 70 , -OC(S)OR 70 , -NR 70 C(O)R 70 , -NR 70 C(S)R 70 , -NR 70 C(O)OR 70 , -NR 70 C(S)OR 70 , -NR 70 C(O)NR 80 R 80 , -NR 70 C(NR 70 )R 70 and -NR 70 C(NR 70 )NR 80 R 80 It is.
[0085] Further to the disclosure herein, in certain embodiments, a substituted group has 1, 2, 3, or 4 substituents, 1, 2, or 3 substituents, 1 or 2 substituents, or 1 substituent.
[0086] Unless otherwise indicated, the nomenclature of substituents not explicitly defined herein is arrived at by naming the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment. For example, the substituent "arylalkyloxycarbonyl" refers to the group (aryl)-(alkyl)-OC(O)-.
[0087] With respect to any of the groups disclosed herein that contain one or more substituents, it is understood that such groups do not of course contain any substitutions or substitution patterns that are sterically infeasible and / or synthetically infeasible. In addition, the subject compounds include all stereochemical isomers arising from the substitution of these compounds.
[0088] "Stereoisomer" and "stereoisomers" refer to compounds that have the same atomic connectivity but different arrangements of atoms in space. Stereoisomers include cis-trans isomers, E and Z isomers, enantiomers, and diastereomers.
[0089] It will be understood that the term "or a salt or solvate or stereoisomer thereof" is intended to include all permutations of the salts, solvates, and stereoisomers, such as solvates of pharmaceutically acceptable salts of the stereoisomers of the subject compounds. It is understood that the term "or a salt thereof" is intended to include all permutations of the salts. It is understood that the term "or a pharmaceutically acceptable salt thereof" is intended to include all permutations of the salts. It is understood that the term "or a solvate thereof" is intended to include all permutations of the solvates. It is understood that the term "or a stereoisomer thereof" is intended to include all permutations of the stereoisomers. It is understood that the term "or a tautomer thereof" is intended to include all permutations of the tautomers. Thus, for example, it will be intended to include solvates of pharmaceutically acceptable salts of the tautomers of the stereoisomers of the subject compounds.
[0090] As used herein, the term "isolated" is meant to describe a compound of interest that is in an environment different from the environment in which the compound naturally occurs. "Isolated" is meant to include compounds within a sample in which the compound of interest is substantially enriched and / or in which the compound of interest is partially or substantially purified.
[0091] Before further describing the present invention, it is to be understood that the invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
[0092] Where a range of values is provided, unless the context clearly dictates otherwise, it is understood that each intervening value between the upper and lower limits, and to one-tenth of the unit of any other value or lower limit of that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limits in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also encompassed within the invention.
[0093] For clarity, it is understood that certain features of the invention described in the context of separate embodiments can also be provided in combination in a single embodiment. Conversely, for brevity, various features of the invention described in the context of a single embodiment can also be provided separately or in any suitable subcombination. All combinations of the embodiments related to the invention are specifically embraced by the present invention and disclosed herein as if each and every combination were individually and explicitly disclosed, to the extent that such combinations include subject matter that is, for example, a compound that is a stable compound (i.e., a compound that can be made, isolated, characterized, and tested for biological activity). In addition, all subcombinations of the various embodiments and their elements (e.g., elements of chemical groups listed in the embodiments describing such variables) are also specifically embraced by the present invention and disclosed herein as if each and every such subcombination were individually and explicitly disclosed herein.
[0094] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.Any methods and materials similar or equivalent to those described herein can also be used to carry out or test this invention, but the methods and materials of interest are described below.All publications mentioned herein are incorporated by reference to disclose and describe the methods and / or materials related to the cited publications.
[0095] It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be written to exclude any optional element. Thus, this statement is intended to serve as a prelude to the use of exclusive terminology, such as "solely," "only," or the use of a "negative" limitation in connection with the recitation of claim elements.
[0096] It will be understood that certain features of an invention that are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention that are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
[0097] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual dates of publication, which may need to be independently confirmed.
[0098] Unless otherwise noted, the methods and techniques of the present embodiment are generally carried out according to conventional methods well known in the art and as described in various general and more specific references cited and discussed throughout this specification. See, for example, Loudon, Organic Chemistry, Fourth Edition, New York: Oxford University Press, 2002, pp. 360-361, 1084-1085; Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-Interscience, 2001.
[0099] The nomenclature used herein to name the subject compounds is illustrated in the Examples herein. Where possible, the nomenclature has generally been derived using the commercially available AutoNom software (MDL, San Leandro, Calif.).
[0100] Many general references are available that provide generally known chemical synthetic schemes and conditions useful for synthesizing the disclosed compounds (see, for example, Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-Interscience, 2001, or Vogel, A Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis, Fourth Edition, New York: Longman, 1978).
[0101] The compounds described herein can be purified by any of the means known in the art, including chromatographic means such as high performance liquid chromatography (HPLC), preparative thin-layer chromatography, flash column chromatography, and ion exchange chromatography.Any suitable stationary phase can be used, including normal phase and reverse phase, and ionic resin.See, for example, Introduction to Modern Liquid Chromatography, 2nd Edition, ed.LRSnyder and JJKirkland, John Wiley and Sons, 1979, and Thin Layer Chromatography, ed E.Stahl, Springer-Verlag, New York, 1969.
[0102] During any of the processes for preparing the compounds of the present disclosure, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules involved. This can be achieved by means of conventional protecting groups as described in such authoritative texts as TW Greene and PG M Huts, "Protective Groups in Organic Synthesis", Fourth edition, Wiley, New York 2006. The protecting groups can be removed at a convenient subsequent stage using methods known in the art.
[0103] The compounds described herein may contain one or more chiral centers and / or double bonds and therefore may exist as stereoisomers, such as double bond isomers (i.e., geometric isomers), enantiomers, or diastereomers. Thus, all possible enantiomers and stereoisomers of the compounds, including stereoisomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure), as well as mixtures of enantiomers and stereoisomers, are included in the description of the compounds herein. Mixtures of enantiomers and mixtures of stereoisomers can be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to those skilled in the art. The compounds may also exist in several tautomeric forms, including enol forms, keto forms, and mixtures thereof. Thus, the chemical structures depicted herein encompass all possible tautomeric forms of the exemplified compounds. The compounds described herein also include isotopically labeled compounds, in which one or more atoms have an atomic mass different from the atomic mass conventionally found in nature. Examples of isotopes that can be incorporated into the compounds disclosed herein include, but are not limited to, 2 H, 3 H, 11 C. 13 C. 14 C. 15 N, 18 O. 17 O and the like. Compounds can exist in non-solvated forms as well as solvated forms, including hydrated forms. In general, compounds can be hydrated or solvated. Certain compounds can exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of this disclosure.
[0104] As summarized above, the present disclosure provides a method for preparing an amorphous solid composition of fatty acid metal salt. In carrying out the subject method according to certain embodiments, a succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base to produce a succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt, and the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is precipitated in a solvent to produce an amorphous solid composition of fatty acid metal salt. The term "succinylation" is used herein in its conventional sense to refer to the addition of a succinyl group (-CO-CH2-CH2-CO2H) to 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane (e.g., the C-2 position of 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane). In embodiments, the succinyl group can be added to 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane by any convenient succinylation protocol, such as, for example, reaction with succinic anhydride in the presence of a base (e.g., an organic base such as triethylamine). By "fatty acid amide" is meant a structural moiety that includes an aliphatic group attached to an amide group (R is C 16 C etc. 10 -C 20 where R' is the C3 carbon of 2-hydroxy-1-(protected hydroxy)propane, -R-CO-N-R'-. In an embodiment (described in more detail below), the fatty acid is 16 Aliphatic chains such as alkyl chains C 10 -C 20 The fatty acid component may be saturated or may contain one or more unsaturations. In some cases, the fatty acid component is fully saturated. In other cases, the fatty acid component is monounsaturated. In still other cases, the fatty acid component is polyunsaturated, such as having two, three, four, or more saturations. In some embodiments, the fatty acid is selected from palmitic acid, stearic acid, oleic acid, linoleic acid, myristoleic acid, and batyl fatty acid.
[0105] The present disclosure describes an amorphous solid composition of fatty acid metal salt. The term "amorphous" is used herein in its conventional sense to refer to a solid material characterized by undefined structural order and microscopic organization that lacks regular geometric arrangement in three dimensions. In some embodiments, the amorphous solid composition of fatty acid metal salt is not crystalline (i.e., a solid material in which the molecules that form the solid are arranged in a highly ordered microscopic geometric organization that extends in three dimensions (e.g., form an ordered lattice-type structure)).
[0106] In embodiments, the organic salt of succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane can include, but is not limited to, triethylamine salt, triethanolamine salt, ammonium salt, arginine salt, benzathine salt, ethylenediamine salt, meglumine salt, procaine salt, N-methylglucamine salt, piperazine salt, tromethamine salt, N,N'-dibenzylethylene-diamine salt, chloroprocaine salt, diethanolamine salt, ethanolamine salt, diisopropylamine salt, diisopropylethylamine salt, among other organic cation salts. In certain embodiments, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt is succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane triethylamine salt.
[0107] The succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base in a solvent. Depending on the desired succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt, the metal base can include, but is not limited to, lithium tert-butoxide, lithium hydroxide, lithium ethoxide, lithium isopropoxide, lithium methoxide, potassium tert-butoxide, potassium hydroxide, potassium ethoxide, potassium isopropoxide, potassium methoxide, sodium tert-butoxide, sodium hydroxide, sodium ethoxide, sodium isopropoxide, sodium methoxide, magnesium tert-butoxide, magnesium hydroxide, magnesium ethoxide, magnesium isopropoxide, magnesium methoxide, calcium tert-butoxide, calcium hydroxide, calcium ethoxide, calcium isopropoxide, calcium methoxide. In embodiments, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted in an amount sufficient to produce a succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt, such as succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane lithium salt, succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane sodium salt, succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane potassium salt, succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane magnesium salt, or succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane calcium salt.
[0108] The amount of metal base contacted with the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt can range from 0.5 equivalents to 2 equivalents of metal base, including 0.75 equivalents to 1.85 equivalents, such as 1 equivalent to 1.8 equivalents, such as 1.05 equivalents to 1.75 equivalents, such as 1.10 equivalents to 1.70 equivalents, such as 1.15 equivalents to 1.65 equivalents, such as 1.2 equivalents to 1.6 equivalents, such as 1.25 equivalents to 1.55 equivalents, and 1.3 equivalents to 1.5 equivalents, relative to the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt, including contacting the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt with 1.5 equivalents of metal salt.
[0109] In embodiments, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base in a solvent. The solvent for contacting the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt with a metal base can be any suitable solvent in which the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt and the metal base are sufficiently soluble, and can be polar or non-polar. In some embodiments, the solvent is non-polar, such as pentane, hexane, heptane, octane, or benzene. In other embodiments, the solvent is a polar solvent, such as dichloromethane, tetrahydrofuran, methyltetrahydrofuran, isopropyl acetate, dimethylformamide, acetonitrile, toluene, 2-methylbutan-2-ol (tAmOH), and N-methyl-2-pyrrolidone. In certain embodiments, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base in dichloromethane. In some embodiments, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base by contacting the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt with a solvent containing a metal base. In these embodiments, the solvent containing the metal base can be a non-polar solvent such as pentane, hexane, heptane, octane, or benzene. In certain embodiments, the solvent is hexane.
[0110] The succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt may be contacted with the metal base at a temperature in the range of -10°C to 10°C, such as -9°C to 9°C, such as -8°C to 8°C, such as -7°C to 7°C, such as -6°C to 6°C, and -5°C to 5°C.
[0111] In some embodiments, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt may be contacted with a metal base at a first temperature, and the reaction mixture is warmed to a second temperature. In one example, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base in a solvent at a first temperature and then warmed to a second temperature. In another example, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt is contacted with a metal base in a solvent at a first temperature for a first period of time and then warmed to a second temperature for a second period of time. In these embodiments, the first temperature may range from -10°C to 0°C, including -9°C to -1°C, such as -8°C to -2°C, such as -7°C to -3°C, and -6°C to -4°C. The second temperature may also range from 0°C to 20°C, including 1°C to 19°C, such as 2°C to 18°C, such as 3°C to 17°C, such as 4°C to 16°C, such as 5°C to 15°C, and 5°C to 10°C. The duration of the first period may vary depending on the concentration of the metal salt and the temperature, and may range from 0.1 minutes to 30 minutes, including 0.5 minutes to 25 minutes, such as 1 minute to 20 minutes, such as 5 minutes to 15 minutes, and 5 minutes to 10 minutes. In some embodiments, the metal base is contacted with the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt and maintained in contact (e.g., stirring the reaction mixture) for the entire duration of the first period. In other embodiments, the metal base is added dropwise (or titrated) into the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt in the solvent over all or a portion of the first period. The duration of the second period may range from 0.1 minutes to 30 minutes, such as 0.5 minutes to 25 minutes, such as 1 minute to 20 minutes, such as 5 minutes to 15 minutes, and including 5 minutes to 10 minutes.
[0112] In some embodiments, the method includes precipitating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt from the reaction mixture to form an amorphous solid. To precipitate the amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt, the reaction mixture is contacted with the same or another non-polar solvent to produce an amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition. The non-polar solvent can include, but is not limited to, pentane, hexane, heptane, octane, benzene, among other non-polar solvents. In certain embodiments, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt reaction mixture is contacted with heptane.
[0113] In some embodiments, the method includes first cooling the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt reaction mixture and then contacting the reaction mixture with a non-polar solvent (e.g., heptane). For example, the reaction mixture may be cooled to a temperature in the range of -10°C to 10°C, including -9°C to 9°C, such as -8°C to 8°C, such as -7°C to 7°C, such as -6°C to 6°C, and -5°C to 5°C.
[0114] In precipitating the amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt, a method according to certain embodiments includes concentrating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt in a non-polar solvent (e.g., heptane), such as by heating or rotary evaporation. The volume of the solvent in the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane reaction mixture can be reduced by 5% or more, including 10% or more, such as 15% or more, such as 20% or more, such as 25% or more, such as 30% or more, such as 35% or more, such as 40% or more, such as 45% or more, such as 50% or more, such as 55% or more, such as 60% or more, such as 65% or more, such as 70% or more, and 75% or more. This may be accomplished by repeatedly adding an amount of non-polar solvent to the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition one or more times, such as two or more times, such as three or more times, and including five or more times, and then further concentrating.
[0115] To precipitate the amorphous succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt from a non-polar solvent, the composition in the non-polar solvent (e.g., heptane) can be first heated to produce a heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition and then cooled to form the amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt. The succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt can be heated in the non-polar solvent to a temperature ranging from 20°C to 60°C, such as from 25°C to 60°C, such as from 40°C to 55°C, and including from 45°C to 55°C. The heated composition may be maintained at the elevated temperature for varying durations, including 1 minute or more, such as 2 minutes or more, such as 5 minutes or more, such as 10 minutes or more, such as 15 minutes or more, such as 30 minutes or more, and 60 minutes or more. In certain embodiments, the method includes heating the composition until the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is solubilized in the solvent, such as by observing a clear solution by visual inspection.
[0116] The heated composition is cooled to precipitate the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt. The heated composition is cooled to a temperature of -20°C to 20°C, including -19°C to 19°C, such as -18°C to 18°C, such as -17°C to 17°C, such as -16°C to 16°C, such as -15°C to 15°C, such as -14°C to 14°C, such as -13°C to 13°C, such as -12°C to 12°C, such as -11°C to 11°C, -10°C to 10°C, and -5°C to 5°C. In certain embodiments, the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition is cooled to 0°C. The cooled composition may be maintained at the reduced temperature (e.g., 0° C.) for varying durations, including 1 minute or more, such as 2 minutes or more, such as 5 minutes or more, such as 10 minutes or more, such as 15 minutes or more, such as 30 minutes or more, and 60 minutes or more. In certain embodiments, the cooled succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition is maintained at the reduced temperature (e.g., 0° C.) for 60 minutes.
[0117] The amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition can be isolated by filtration (e.g., vacuum filtration) or the solvent can be removed by heating or rotary evaporation. In certain embodiments, the amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition is isolated by drying under a nitrogen atmosphere or under vacuum at room temperature. In some embodiments, the amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is isolated at a temperature between -20°C and 20°C, including -19°C to 19°C, such as -18°C to 18°C, such as -17°C to 17°C, such as -16°C to 16°C, such as -15°C to 15°C, such as -14°C to 14°C, such as -13°C to 13°C, such as -12°C to 12°C, such as -11°C to 11°C, -10°C to 10°C, and -5°C to 5°C. In certain embodiments, the amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is isolated at 0°C.
[0118] In some embodiments, the method includes precipitating an amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt by inverse addition of a non-polar solvent to the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt reaction mixture. In this embodiment, a certain amount of succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt reaction mixture is contacted with a non-polar solvent. The non-polar solvent can include, but is not limited to, pentane, hexane, heptane, octane, benzene, among other non-polar solvents. In certain cases, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt reaction mixture is contacted with heptane.
[0119] The reaction mixture contacted with the non-polar solvent is concentrated, such as by heating or rotary evaporation. The volume of the reaction mixture can be reduced by 5% or more, including 10% or more, such as 15% or more, such as 20% or more, such as 25% or more, such as 30% or more, such as 35% or more, such as 40% or more, such as 45% or more, such as 50% or more, such as 55% or more, such as 60% or more, such as 65% or more, such as 70% or more, and 75% or more. This may be accomplished by repeatedly adding an amount of non-polar solvent to the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition one or more times, including two or more times, three or more times, and five or more times, and then concentrating further.
[0120] To precipitate the amorphous succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt from the non-polar solvent, the composition is heated to produce a heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition. The composition may be heated in the non-polar solvent to a temperature ranging from 20° C. to 60° C., such as from 25° C. to 60° C., such as from 40° C. to 55° C., and including from 45° C. to 55° C. The heated composition may be maintained at the elevated temperature for varying durations, such as from 1 minute or more, such as from 2 minutes or more, such as from 5 minutes or more, such as from 10 minutes or more, such as from 15 minutes or more, such as from 30 minutes or more, and including from 60 minutes or more. In certain embodiments, the method includes heating the composition until the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is solubilized in the solvent, such as by observing a clear solution by visual inspection.
[0121] To cool the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition, the heated composition is contacted with a cold non-polar solvent (e.g., heptane). In these embodiments, the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition can be added to a non-polar solvent (e.g., heptane) that is at a temperature of -20°C to 20°C, including -19°C to 19°C, such as -18°C to 18°C, such as -17°C to 17°C, such as -16°C to 16°C, such as -15°C to 15°C, such as -14°C to 14°C, such as -13°C to 13°C, such as -12°C to 12°C, such as -11°C to 11°C, such as -10°C to 10°C, and -5°C to 5°C. In certain embodiments, the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition is contacted with a non-polar solvent that is at a temperature of −10° C. The cooled composition can be maintained at a reduced temperature (e.g., 0° C.) for varying durations, including 0.1 hours or more, such as 0.5 hours or more, such as 1 hour or more, such as 1.5 hours or more, such as 2 hours or more, such as 2.5 hours or more, and 3 hours or more. In certain embodiments, the cooled succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition is maintained at a reduced temperature (e.g., 0° C.) for 3 hours.
[0122] In certain embodiments, the method includes subjecting the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition to one or more heating / cooling cycles. In these embodiments, each heating / cooling cycle includes heating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition to a first temperature and maintaining the composition at the first temperature for a first period of time, followed by cooling the heated composition to a second temperature and maintaining the cooled composition at the second temperature for a second period of time. In these embodiments, the first temperature is in the range of 10° C. to 30° C., including 15° C. to 25° C., and up to a temperature of 20° C., and the first period of time is in the range of 30 minutes to 60 minutes, including 35 minutes to 55 minutes, and including 40 minutes to 50 minutes. The second temperature is in the range of -10°C to 10°C, such as -5°C to 5°C, and including 0°C, and the second time period is in the range of 45 minutes to 90 minutes, such as 50 minutes to 85 minutes, such as 55 minutes to 80 minutes, and including 60 minutes to 75 minutes. The heating / cooling cycle may be repeated one or more times, such as two or more times, and including three or more times.
[0123] The precipitated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition in the non-polar solvent may be maintained at a reduced temperature for a period of time prior to isolation. In some cases, the precipitated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition is maintained in the non-polar solvent at a temperature ranging from -10°C to 10°C, such as from -5°C to 5°C, and including 0°C. The precipitated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition may be maintained at a reduced temperature for a varying period of time, such as 1 hour or more, such as 2 hours or more, such as 4 hours or more, such as 8 hours or more, such as 12 hours or more, and including 16 hours or more.
[0124] The amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition can be isolated by filtration (e.g., vacuum filtration) or the solvent can be removed by heating or rotary evaporation. In certain embodiments, the amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition is isolated by drying under a nitrogen atmosphere or under vacuum at room temperature. In some embodiments, the amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is isolated at a temperature between -20°C and 20°C, including -19°C to 19°C, such as -18°C to 18°C, such as -17°C to 17°C, such as -16°C to 16°C, such as -15°C to 15°C, such as -14°C to 14°C, such as -13°C to 13°C, such as -12°C to 12°C, such as -11°C to 11°C, -10°C to 10°C, and -5°C to 5°C. In certain embodiments, the amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is isolated at 0°C. The isolated amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt may be dried to remove any residual solvent, such as under vacuum at ambient temperature.
[0125] In certain embodiments, the method further comprises preparing a succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt by contacting 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane with succinic anhydride in the presence of an organic base. The amount of succinic anhydride contacted with the 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane can vary from 0.75 equivalents to 1.95 equivalents, such as 1 equivalent to 1.9 equivalents, such as 1.1 equivalents to 1.85 equivalents, such as 1.15 equivalents to 1.80 equivalents, such as 1.25 equivalents to 1.75 equivalents, and including contacting the 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane with 1.2 equivalents of succinic anhydride.
[0126] Depending on the type of organic salt desired, the organic base used may include, but is not limited to, triethylamine, triethanolamine, ammonia, arginine, benzathine, ethylenediamine, meglumine, procaine, N-methylglucamine, piperazine, tromethamine, N,N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, ethanolamine, diisopropylamine, diisopropylethylamine, among other organic bases. In these embodiments, 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane is contacted with succinic anhydride in a polar solvent such as dichloromethane, tetrahydrofuran, methyltetrahydrofuran, isopropyl acetate, dimethylformamide, acetonitrile, toluene, 2-methylbutan-2-ol (tAmOH), and N-methyl-2-pyrrolidone. The amount of organic base used can vary from 2.6 equivalents to 3.4 equivalents, such as 2.7 equivalents to 3.3 equivalents, such as 2.8 equivalents to 3.2 equivalents, such as 2.9 equivalents to 3.1 equivalents, and from 2.5 equivalents to 3.5 equivalents of organic base relative to the 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane, including contacting the 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane with 3.0 equivalents of organic base (e.g., trimethylamine).
[0127] The 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane may be contacted with succinic anhydride in the presence of an organic base at a temperature in the range of 10° C. to 30° C., such as 12° C. to 28° C., such as 14° C. to 26° C., including 16° C. to 24° C., and 18° C. to 22° C.
[0128] The components used in each step of the subject method for preparing the amorphous succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salts described herein can be purified or crude compositions, as desired. The term "purified" is used in its conventional sense to refer to a composition that has undergone at least some isolation or purification process, such as, for example, filtration of the reaction mixture or aqueous workup. In certain cases, purification includes liquid chromatography, recrystallization, distillation (e.g., azeotropic distillation), or other types of compound purification. In some embodiments, the reaction mixture is used as a crude mixture in a subsequent step in the method described herein. The term "crude" is used herein in its conventional sense to refer to a composition that has not undergone purification or other workup of the reaction mixture. In certain cases, the crude composition reaction mixture is used in a crude composition that has undergone purification or other workup by high performance liquid chromatography (HPLC), proton nuclear magnetic resonance spectroscopy ( 1 The composition may contain the compound of interest in sufficient purity, such as containing the compound of interest in a purity of 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, such as 96% or more, 97% or more, such as 98% or more, and 99% or more, as determined by H NMR, or a combination thereof. For example, in certain embodiments above, the method includes preparing a succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt by contacting 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane with succinic anhydride in the presence of an organic base. In these embodiments, the method may include contacting the crude composition of succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt directly (i.e., without any purification or workup) with a metal base to produce the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt.
[0129] In embodiments, the fatty acid of the 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane compounds (i.e., organic salts, metal salts, etc.) described herein can vary, and in certain cases the fatty acid is selected from palmitic acid, stearic acid, oleic acid, linoleic acid, myristoleic acid, and batyl fatty acid.
[0130] The protected hydroxy group of the 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane compounds described herein may also vary in certain cases, with hydroxyl protecting groups including, but not limited to, 1) alkyl ether type protecting groups, such as alkyl ether, allyl ether, triphenylmethyl ether, dimethoxy-triphenylmethyl ether, benzyl ether, or p-methoxybenzyl ether protecting groups; 2) acetate, chloroacetate, dichloroacetate, tri ... Fluoroacetate, trifluoroacetate, pivaloate, benzoate, p-methoxybenzoate, p-bromobenzoate, methyl carbonate, 9-(fluorenylmethyl)carbonate (Fmoc), allyl carbonate (Alloc), 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (Teoc), benzyl carbonate (Cbz), t-butyl carbonate (Boc), or dimethylthiocarbmate (DMTC) ester and carbonate type protecting groups such as methoxymethyl ether (MOM), benzyloxymethyl ether (BOM), 2,2,2-trichloroethoxymethyl ether, 2-methoxymethyl ether (MEM), methylthiomethyl ether (MTM), p-methoxybenzyloxymethyl ether (PMBM), 2-(trimethylsilyl)ethoxymethyl ether (SEM), tetrahydropyranyl ether (THP) protecting groups, and 2) silyl ether type protecting groups such as trimethylsilyl (TMS), triethylsilyl (TES), isopropyldimethylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), t-butyldimethylsilyl (TBS), t-butyldiphenylsilyl (TBDPS), triisopropylsilyl (TIPS), tetraisopropyldisiloxanylidene (TIPDS), or di-t-butylsilylene (DTBS) protecting groups. In certain embodiments, the protected hydroxy group of the 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane compounds described herein is a dimethoxy-triphenylmethyl protecting group.
[0131] In certain embodiments, the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is a compound of formula I. [ka]
[0132] In some embodiments, the present disclosure also provides an amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane lithium salt of formula I having a peak at about 19.5° 2θ in an X-ray powder diffraction pattern (XRPD, FIG. 1) using Cu Kα radiation. In other embodiments, the present disclosure provides an amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane lithium salt of formula I in which a thermogravimetric analysis (TGA, FIG. 3) exhibits a single weight loss step. In these embodiments, the single weight loss step may begin at about 225° C. The subject amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane lithium salt of formula I may also be characterized by a TGA thermogram that exhibits a mass loss of less than 1% of the total mass of the sample upon heating between 30° C. and 300° C. In another embodiment, the present disclosure provides an amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane lithium salt of formula I, wherein the differential scanning calorimetry (DSC, FIG. 4) curve exhibits an absorption peak at about 44.9° C.
[0133] Aspects of the disclosure Aspects of the subject matter described herein, including embodiments, may be useful alone or in combination with one or more other aspects or embodiments. Without limiting the disclosure, certain non-limiting aspects of the disclosure numbered 1-32 are provided below. As will be apparent to one of skill in the art upon reading this disclosure, each of the individually numbered aspects may be used or combined with any of the preceding or succeeding individually numbered aspects. This is intended to support the support of all such combinations of aspects, and is not limited to the combinations of aspects explicitly provided below.
[0134] 1. A method for preparing an amorphous solid composition comprising a fatty acid metal salt, the method comprising: contacting the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt with a metal base to produce a succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt; and precipitating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt to produce an amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition. 2. The method of embodiment 1, wherein the amorphous solid composition is a crude composition. 3. The crude composition is purified by high performance liquid chromatography (HPLC), proton nuclear magnetic resonance spectroscopy ( 1 3. The method of embodiment 2, comprising a fatty acid metal salt having a purity of 90% or greater as determined by NMR, NMR spectrum, NMR spectroscopy, or a combination thereof. 4. The method of any one of aspects 1 to 3, wherein the crude reaction product is carried through all steps of the method. 5. A method, comprising the steps of: high performance liquid chromatography (HPLC), proton nuclear magnetic resonance spectroscopy ( 1 H NMR), or a combination thereof, is sufficient to obtain an isolated yield of 90% or greater of the fatty acid metal salt. 6. The method of any one of the preceding aspects, further comprising contacting the 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane with succinic anhydride in a polar solvent in the presence of an organic base. 7. The method of embodiment 6, wherein the polar solvent comprises dichloromethane. 8. Precipitating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt heating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt in a non-polar solvent to produce a heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition; and cooling the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition to form an amorphous solid of succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt. 9. The method of embodiment 8, wherein cooling the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition comprises adding the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition back to a cold non-polar solvent. 10. The method of embodiment 8 or 9, wherein the method comprises heating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt in a non-polar solvent to a temperature of 45-55° C. 11. The method of any one of aspects 8-10, wherein the method comprises cooling the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition to a temperature of -10 to 0 °C. 12. The method of any one of aspects 8-11, wherein the non-polar solvent comprises heptane. 13. The method of any one of aspects 8-12, wherein an amorphous solid of succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is isolated. 14. The method of any one of aspects 1-13, wherein the amorphous solid of succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is isolated by vacuum filtration. 15. The method of any one of aspects 1-14, wherein the fatty acid is selected from the group consisting of palmitic acid, stearic acid, oleic acid, linoleic acid, myristoleic acid, and batyl fatty acid. 16. The method of claim 15, wherein the fatty acid is palmitic acid. 17. The method of any one of the preceding aspects, wherein the protected hydroxy group comprises a dimethoxy-triphenylmethyl protecting group. 18. 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane is a compound of formula II, [ka] A method according to any one of the preceding aspects, wherein DMT is dimethoxy-triphenylmethyl. 19. The method of any one of the preceding aspects, wherein the organic salt is a triethylamine salt. 20. The method of any one of the preceding aspects, wherein the metal base is selected from lithium hydroxide and lithium tert-butoxide. 21. A metal base in lithium tert-butoxide, as described in embodiment 20. 22. The method of any one of aspects 1-21, wherein the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is a compound of formula I. [ka] 23. Amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane lithium salt. 24. The amorphous salt according to aspect 23, wherein the fatty acid is selected from the group consisting of palmitic acid, stearic acid, oleic acid, linoleic acid, myristoleic acid, and batyl fatty acid. 25. The amorphous salt according to aspect 24, wherein the fatty acid is palmitic acid. 26. The amorphous salt of any one of aspects 23-25, wherein the protected hydroxy group comprises a dimethoxy-triphenylmethyl protecting group. 27. The amorphous salt of any one of aspects 23-26, wherein the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is a compound of formula I. [ka] 28. The amorphous salt of embodiment 27, having an X-ray powder diffraction pattern (XRPD) comprising a peak at about 19.5° 2θ. 29. The amorphous salt according to aspect 27 or 28, wherein a thermogravimetric analysis (TGA) of the amorphous salt is characterized by a single weight loss step. 30. The amorphous salt according to embodiment 29, wherein the weight loss step begins at about 225° C. 31. The amorphous salt of any one of aspects 27-30, wherein the amorphous salt has a TGA thermogram that exhibits a mass loss of less than 1% of the total mass of the sample upon heating between 30° C. and 300° C. 32. The amorphous salt of any one of aspects 27-31, having an absorption peak at about 44.9° C. by differential scanning calorimetry (DSC). EXAMPLES
[0135] The following examples are presented to provide those of skill in the art with a complete disclosure and description of how to make and use the invention, and are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent that the following experiments are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.), but some experimental error and deviation must be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weights are weight average molecular weights, temperatures are in degrees Celsius, and pressures are at or near atmospheric pressure. "Average" means the arithmetic mean. Standard abbreviations may be used, such as bp, base pairs; kb, kilobases; pl, picoliters; s or sec, seconds; min, minutes; h or hr, hours; aa, amino acids; kb, kilobases; bp, base pairs; nt, nucleotides; im, intramuscular; intraperitoneal; sc, subcutaneous, etc.
[0136] General synthetic procedure Many general references are available that provide generally known chemical synthetic schemes and conditions useful for synthesizing the disclosed compounds (see, for example, Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-Interscience, 2001, or Vogel, A Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis, Fourth Edition, New York: Longman, 1978).
[0137] The compounds described herein can be purified by any purification protocol known in the art, including chromatography such as HPLC, preparative thin-layer chromatography, flash column chromatography, and ion exchange chromatography.Any suitable stationary phase can be used, including normal phase and reverse phase, and ionic resin.In certain embodiments, the disclosed compounds are purified through silica gel and / or alumina chromatography.See, for example, Introduction to Modern Liquid Chromatography, 2nd Edition, ed.L.Snyder and J.J.Kirkland, John Wiley and Sons, 1979, and Thin Layer Chromatography, ed.E.Stahl, Springer-Verlag, New York, 1969.
[0138] During any of the processes for preparing the subject compounds, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules involved. This is described in detail in JFW MacOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973; TW Greene, and PG M Huts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999; "The Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981; "Methoden der organischen Chemie", Houben-Weyl, 4 thedition, Vol. 15 / l, Georg Thieme Verlag, Stuttgart 1974, H.-D. Jakubke and H. Jescheit, "Aminosauren, Peptide, Protein", Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and / or Jochen Lehmann, "Chemie der Kohlenhydrate: Monosaccharide and Derivate", Georg Thieme Verlag, Stuttgart 1974. The protecting groups may be removed at a convenient subsequent stage using methods known in the art.
[0139] The subject compounds can be synthesized through a variety of different synthetic routes using commercially available starting materials and / or starting materials prepared by conventional synthetic methods.Various examples of synthetic routes that can be used to synthesize the compounds disclosed herein are described in the following schemes.
[0140] Example 1 - Preparation of amorphous solid succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethyl-protected hydroxy)-propane lithium salt from 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethyl-protected hydroxy)-propane (Scheme II) [ka]
[0141] 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethyl-protected hydroxy)-propane (A) was contacted with succinic anhydride in dichloromethane in the presence of triethylamine. The solution was stirred at room temperature for 3 hours to form, without isolation, the succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethyl-protected hydroxy)-propane triethylamine salt intermediate (B). The succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethyl-protected hydroxy)-propane triethylamine salt intermediate was diluted with ethyl acetate and cooled to 0-5°C, followed by addition of aqueous LiOH and stirring at 0-5°C for 5-10 minutes. The aqueous layer, and the organic layer containing the lithium salt, were separated, and the organic layer was washed with LiCl. The organic layer was again separated and concentrated by rotary evaporation. The concentrate was diluted with ethyl acetate and poured through a sintered glass funnel. The clear filtrate was concentrated by rotary evaporation and dried by vacuum pump until a foamy solid was formed. Heptane was added to the foamy solid and heated to 50° C. until clear. The clear solution was cooled to 45° C. over 1 hour until cloudiness occurred. Further cooling to 20° C. over 1 hour resulted in the formation of a gummy solid. The composition was further cooled to 5-10° C. until it formed a hard solid. The slurry containing the hard solid was stirred overnight at 10° C. The hard solid was isolated by filtration and dried under vacuum with a nitrogen blanket at room temperature for 30 minutes. The solid was further dried under vacuum at ambient temperature for 16 hours.
[0142] Example 2 - Preparation of amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane lithium salt - normal addition mode The succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethyl-protected hydroxy)-propane triethylamine salt was converted to the lithium salt via non-aqueous treatment with 1N LiOtBu in hexane. The crude succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethyl-protected hydroxy)-propane organic salt composition was cooled to 0-5°C followed by the addition of 1N LiOtBu in hexane (1.15 equiv.) and stirring at 0-5°C for 5-10 minutes. Heptane was added to the composition and concentrated to 10-15 mL by rotary evaporation. The addition of heptane and concentration by rotary evaporation was repeated twice. The lithium salt composition in heptane was heated to 50°C until clear. The heated composition was maintained at 50°C under stirring for 10-15 minutes followed by cooling to 0°C over 1 hour until the formation of a gummy semi-solid. The slurry was aged at 0° C. for 3 hours and then filtered under nitrogen gas at 0° C. The solid was further dried under nitrogen and partial vacuum at 0° C. for 30 minutes and then at 10° C. for 30 minutes. The solid succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethyl protected hydroxy)-propane lithium salt was dried under vacuum at room temperature for 16 hours.
[0143] A dried, free-flowing solid having a purity of greater than 99.0A by HPLC was obtained in 91% isolated yield (uncorrected), which was 1 H NMR (DMSO-d6) demonstrated succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethyl protected hydroxy)-propane lithium salt.
[0144] Example 3 - Preparation of amorphous solid succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt - Reverse addition mode In order to avoid phase transition through an oily / sticky phase, a back addition of hot T375-Li / heptane solution to cold heptane was designed and tested. The experiment was carried out in a 100 mL EasyMax container with vigorous mixing. A hot (50° C.) heptane solution of succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt described in Example 1 was added slowly (in small portions) to cold (−10° C.) heptane. Succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt solid immediately precipitated as a uniform fine solid. The formed slurry in heptane was aged at 0° C. for 3 hours. The cooled slurry was subjected to a heat / cool cycle in which it was heated from 0° C. to 20° C. over 40 minutes, held at 20° C. for 10 minutes, then cooled to 0° C. over 1 hour and held at 0° C. for 1 hour. The heat / cool cycle was repeated two times, and the slurry was then aged at 0° C. for 16 hours. The slurry batch temperature was maintained between 0° C. and 10° C., and no oily or sticky material was observed during or after the addition of the succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt solution.
[0145] Fast filtration rate of the final succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt solid showed an increase in particle size with heating-cooling cycles. Deliquor was performed under vacuum with nitrogen protection at ambient temperature. The wet cake was dried overnight in a flask under vacuum at ambient temperature. The isolated succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt product (4.92 g) provided a 91% yield (uncorrected). It should be noted that there was no impurity elimination with the mother liquor, the product loss in the mother liquor was 4.6% by HPLC analysis.
[0146] The isolated dry solid of succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt from the reverse addition protocol was characterized by X-ray powder diffraction (XRPD, Figure 1), polarized light microscopy (PLM, Figure 2), thermogravimetric analysis (TGA, Figure 3) and differential scanning calorimetry (DSC, Figure 4). Elemental analysis revealed an observed lithium content of 1.36 wt% versus a theoretical value of 0.94 wt%.
[0147] Example 4 - Physical stability of amorphous solid succinylated 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt The physical stability of amorphous 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt was tested at room temperature under different relative humidities (RH). 300 mg of amorphous 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt was placed in an uncapped scintillation vial at 11% RH, 33% RH, and 75% RH for several days. (Table 1) [Table 1]
[0148] As shown in Table 1, the amorphous 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt remained solid for extended periods of time at room temperature and up to 33% relative humidity. The lithium salt is a stable solid that is easily isolated and stored, compared to the 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane organic salt, which formed a viscous sticky liquid at room temperature. The lithium salt is also highly soluble in most organic solvents at near ambient temperatures. The high stability, ready storage, and high solubility make the 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane lithium salt a better starting material for use in the synthesis of compounds containing fatty acid amide linkers (e.g., imetelstat) compared to the 3-(palmitoylamido)-2-hydroxy-1-(dimethoxytriphenylmethylhydroxy)-propane organic salt. In one embodiment, for example, the following items are provided: (Item 1) 1. A method for preparing an amorphous solid composition comprising a fatty acid metal salt, the method comprising: contacting the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt with a metal base to produce a succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt; and precipitating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt to produce an amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition. (Item 2) 2. The method of claim 1, wherein the amorphous solid composition is a crude composition. (Item 3) The crude composition is purified by high performance liquid chromatography (HPLC), proton nuclear magnetic resonance spectroscopy ( 1 3. The method according to claim 2, comprising the fatty acid metal salt having a purity of 90% or greater as determined by NMR, NMR spectroscopy ... (Item 4) 4. The process according to any one of items 1 to 3, wherein the crude reaction product is carried through all steps of the process. (Item 5) The method may be performed by high performance liquid chromatography (HPLC), proton nuclear magnetic resonance spectroscopy ( 1 1 H NMR), or a combination thereof, is sufficient to obtain the fatty acid metal salt in an isolated yield of 90% or greater. (Item 6) 6. The method according to any one of items 1 to 5, further comprising contacting 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane with succinic anhydride in a polar solvent in the presence of an organic base. (Item 7) 7. The method of claim 6, wherein the polar solvent comprises dichloromethane. (Item 8) Precipitating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt comprises heating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt in a non-polar solvent to produce a heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition; and cooling the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition to form an amorphous solid of the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt. (Item 9) 9. The method of claim 8, wherein cooling the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition comprises adding the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition back to a cold non-polar solvent. (Item 10) 10. The method according to claim 8 or 9, wherein the method comprises heating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt in the non-polar solvent to a temperature of 45 to 55°C. (Item 11) 11. The method according to any one of items 8 to 10, wherein the method comprises cooling the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition to a temperature of -10 to 0°C. (Item 12) 12. The method according to any one of items 8 to 11, wherein the non-polar solvent comprises heptane. (Item 13) 13. The method according to any one of items 8 to 12, wherein the amorphous solid of the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is isolated. (Item 14) 14. The method according to any one of items 1 to 13, wherein the amorphous solid of the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is isolated by vacuum filtration. (Item 15) 15. The method according to any one of items 1 to 14, wherein the fatty acid is selected from the group consisting of palmitic acid, stearic acid, oleic acid, linoleic acid, myristoleic acid, and batyl fatty acid. (Item 16) 16. The method of claim 15, wherein the fatty acid is palmitic acid. (Item 17) 17. The method of any one of items 1 to 16, wherein the protected hydroxy group comprises a dimethoxy-triphenylmethyl protecting group. (Item 18) The 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane is a compound of formula II,
change
change
change
Claims
1. 1. A method for preparing an amorphous solid composition comprising a succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt, the method comprising: contacting 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane with succinic anhydride in a polar solvent in the presence of an organic base to produce a succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt; contacting the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane organic salt with a metal base to produce a succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt, as shown in Scheme I; and precipitating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt to produce an amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition. 【Chemistry 12】 In the formula, R is C 10 -C 20 It is a fatty acid, + The method wherein Org is an organic cation and PG is a protecting group.
2. The method of claim 1 , wherein the amorphous solid composition is prepared without a purification step.
3. The composition may be analyzed by high performance liquid chromatography (HPLC), proton nuclear magnetic resonance spectroscopy ( 1 3. The method of claim 2, wherein the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt has a purity of 90% or greater as determined by NMR, 1 H NMR, or a combination thereof.
4. The method may be performed using high performance liquid chromatography (HPLC), proton nuclear magnetic resonance spectroscopy ( 1 1 H NMR), or a combination thereof, is sufficient to obtain the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt in 90% or greater isolated yield.
5. The method of claim 1 , wherein the polar solvent comprises dichloromethane.
6. precipitating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt; heating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt in a non-polar solvent to produce a heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition; and cooling the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition to form an amorphous solid of the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt.
7. 7. The method of claim 6, wherein cooling the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition comprises adding the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition back to a non-polar solvent.
8. 7. The method of claim 6, wherein the method comprises heating the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt in the non-polar solvent to a temperature of 45-55°C.
9. 7. The method of claim 6, wherein the method comprises cooling the heated succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt composition to a temperature of from -10 to 0°C.
10. The method of claim 6 , wherein the non-polar solvent comprises heptane.
11. 7. The method of claim 6, wherein the amorphous solid of the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is isolated.
12. 10. The method of claim 1, wherein the amorphous solid of the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is isolated by vacuum filtration.
13. 2. The method of claim 1, wherein the fatty acid is selected from the group consisting of palmitic acid, stearic acid, oleic acid, linoleic acid, and myristoleic acid.
14. The method of claim 13, wherein the fatty acid is palmitic acid.
15. The method of claim 1, wherein the protected hydroxy group comprises a dimethoxy-triphenylmethyl protecting group.
16. The 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane is a compound of formula II, 【Chemistry 9】 2. The method of claim 1, wherein DMT is dimethoxy-triphenylmethyl.
17. The method of claim 1 , wherein the organic salt is a triethylamine salt.
18. 2. The method of claim 1, wherein the metal base is selected from lithium hydroxide and lithium tert-butoxide.
19. The method of claim 18, wherein the metal base is lithium tert-butoxide.
20. 2. The method of claim 1, wherein the succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane metal salt is a compound of formula I 【Chemistry 10】 。
Citation Information
Patent Citations
Modified oligonucleotides for telomerase inhibition
JP2007504830A
Improved process for preparing imetelstat
WO2019011829A1
